Preoperative HALP Profiles in Serous and Mucinous Epithelial Ovarian Tumors: Positioning Borderline Tumors on the Benign-Malignant Spectrum.
- 1Department of Obstetrics and Gynecology, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul 34722, Türkiye.
- 2Department of Obstetrics and Gynecology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul 34700, Türkiye.
Abstract
Background/Objectives: Borderline ovarian tumors can overlap with benign and malignant adnexal masses in their preoperative features. The hemoglobin-albumin-lymphocyte-platelet (HALP) score reflects inflammatory and immunonutritional status. We compared HALP profiles across benign, borderline, and malignant epithelial ovarian tumors and secondarily explored their contribution beyond the risk of malignancy index (RMI). Methods: This retrospective single-center study included 464 women treated surgically for serous or mucinous epithelial ovarian tumors between 2015 and 2025: 164 benign cystadenomas, 78 borderline tumors, and 222 invasive carcinomas. HALP was compared among groups with additional adjustment for age and menopausal status. Regression and model-performance analyses were performed only in the borderline and malignant groups (n = 300). Results: Median HALP was lower in malignant tumors [28.6 (IQR 22.4)] than in benign [38.3 (23.8)] and borderline tumors [40.5 (21.4)] (both p < 0.001), whereas benign and borderline tumors were similar (p = 0.948). After adjustment, HALP remained lower in malignant tumors than in benign (adjusted median difference, -10.49; 95% CI, -15.47 to -4.55) and borderline tumors (-11.86; 95% CI, -18.63 to -5.84). In exploratory malignant-versus-borderline modeling, HALP was associated with malignant histology alone, but this association was attenuated after accounting for age and log-transformed RMI; adding HALP did not significantly improve model fit or discrimination. Conclusions: Preoperative HALP was consistently lower in malignant tumors, while borderline tumors resembled benign lesions. HALP may reflect systemic immunonutritional differences across pathological groups. Its incremental predictive role beyond established preoperative measures remains uncertain and requires external validation.
Related
- Characterization of Clinical and Histopathological Profiles of Oral Potentially Malignant Disorders With Oral Epithelial Dysplasia: Focus on Subepithelial Lymphoplasmacytic Infiltrate and Its Grading
- Malignant transformation of endometriosis into endometrioid ovarian carcinoma with a contralateral borderline seromucinous tumour: A rare case report.
- Case Report: Diagnostic pitfalls and individualized surgical management of borderline and malignant phyllodes tumors: a three-case series
- From inflammation to carcinogenesis: MiRNA regulates epithelial-mesenchymal transition to facilitate malignant progression of gastric precancerous lesions
- Copper homeostasis dysregulation promotes malignant transformation of renal tubular epithelial cells via the ROS/NF-κB/AID signaling axis
BibTeX
@article{cim2026preoperative,
title = {{Preoperative HALP Profiles in Serous and Mucinous Epithelial Ovarian Tumors: Positioning Borderline Tumors on the Benign-Malignant Spectrum.}},
author = {Hanne Bulat Cim and Nisan Helin Dönmez and Melis Altuğ Inan and Fatma Ceren Gurel and Başak Cantürk Murt and Neslişah Ar and Ergül Demircivi and Abdulkadir Turgut},
journal = {Journal of clinical medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15197662},
url = {https://europepmc.org/article/MED/42882123},
note = {CC BY},
}
RIS
TY - JOUR
TI - Preoperative HALP Profiles in Serous and Mucinous Epithelial Ovarian Tumors: Positioning Borderline Tumors on the Benign-Malignant Spectrum.
AU - Hanne Bulat Cim
AU - Nisan Helin Dönmez
AU - Melis Altuğ Inan
AU - Fatma Ceren Gurel
AU - Başak Cantürk Murt
AU - Neslişah Ar
AU - Ergül Demircivi
AU - Abdulkadir Turgut
PY - 2026
DA - 2026/10/03
JO - Journal of clinical medicine
DO - 10.3390/jcm15197662
UR - https://europepmc.org/article/MED/42882123
AB - Background/Objectives: Borderline ovarian tumors can overlap with benign and malignant adnexal masses in their preoperative features. The hemoglobin-albumin-lymphocyte-platelet (HALP) score reflects inflammatory and immunonutritional status. We compared HALP profiles across benign, borderline, and malignant epithelial ovarian tumors and secondarily explored their contribution beyond the risk of malignancy index (RMI). Methods: This retrospective single-center study included 464 women treated surgically for serous or mucinous epithelial ovarian tumors between 2015 and 2025: 164 benign cystadenomas, 78 borderline tumors, and 222 invasive carcinomas. HALP was compared among groups with additional adjustment for age and menopausal status. Regression and model-performance analyses were performed only in the borderline and malignant groups (n = 300). Results: Median HALP was lower in malignant tumors [28.6 (IQR 22.4)] than in benign [38.3 (23.8)] and borderline tumors [40.5 (21.4)] (both p < 0.001), whereas benign and borderline tumors were similar (p = 0.948). After adjustment, HALP remained lower in malignant tumors than in benign (adjusted median difference, -10.49; 95% CI, -15.47 to -4.55) and borderline tumors (-11.86; 95% CI, -18.63 to -5.84). In exploratory malignant-versus-borderline modeling, HALP was associated with malignant histology alone, but this association was attenuated after accounting for age and log-transformed RMI; adding HALP did not significantly improve model fit or discrimination. Conclusions: Preoperative HALP was consistently lower in malignant tumors, while borderline tumors resembled benign lesions. HALP may reflect systemic immunonutritional differences across pathological groups. Its incremental predictive role beyond established preoperative measures remains uncertain and requires external validation.
SN - 2077-0383
ER -